Studies have shown that active fund managers routinely underperform the S&P500 index*​

Dyne Therapeutics, Inc. (NASDAQ: DYN)

DYN Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
104.20%

DYN Stock Analysis

DYN PE Ratio:

DYN PEG Ratio: Not Available

DYN Forward EPS Growth (12 month): 0.00%

DYN PS Ratio:

DYN PSG Ratio: Not Available

DYN Forward Revenue Growth (12 month): 0.00%

DYN Articles

No data was found